BMJ Oncology (Jul 2024)

Surgical management of skull base chordomas and chondrosarcomas: insights from a national cohort study

  • Rekha Siripurapu,
  • Laurence J Glancz,
  • Omar N Pathmanaban,
  • Charlotte Hammerbeck-Ward,
  • Cathal John Hannan,
  • Alexandros Vyziotis,
  • Scott A Rutherford,
  • Gillian A Whitfield,
  • Adrian Crellin,
  • Gillian M Potter,
  • Andrew Thomas King,
  • Raj K Bhalla,
  • Shermaine Pan,
  • Rovel Colaco

DOI
https://doi.org/10.1136/bmjonc-2024-000386
Journal volume & issue
Vol. 3, no. 1

Abstract

Read online

Objective Skull base chordoma and chondrosarcoma are distinct sarcomas of the skull base but share significant therapeutic challenges due to their proximity to critical neurovascular structures, making surgical resection difficult. We sought to establish factors associated with outcome predictors in a national cohort of patients.Methods and analysis Data for all patients referred with a diagnosis of skull base chordoma or chondrosarcoma from April 2017 to December 2022 were obtained. We performed analyses of data pertaining to the first cohort of patients treated in the UK with proton beam therapy (PBT) to determine factors associated with obtaining gross total resection (GTR) and adequate clearance of the brainstem and optic apparatus.Results Of 230 patients with skull base chordoma or chondrosarcoma referred for PBT, 71% were accepted for PBT, with a wide regional variation between referring neurosurgical units (29%–93%). Of the first 75 consecutive patients treated with PBT, the only factor predictive of obtaining GTR was surgical resection at a unit with higher volumes of patients accepted for PBT (OR 1.32, 95% CI 1.11 to 1.63, p=0.004). Use of intraoperative MRI (OR 4.84, 95% CI 1.21 to 27.83, p=0.04) and resection at a higher volume unit (OR 1.29, 95% CI 1.07 to 1.64, p=0.013) were associated with increased rates of tumour clearance from the brainstem/optic apparatus.Conclusions Treatment at a higher volume centre was a key determinant of the optimal surgical outcome in this cohort. These data support the management of skull base chordomas and chondrosarcomas in higher volume centres where multidisciplinary experience can be accumulated.